Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)


1. CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain
2. Prostate Cancer Research Unit, Spanish National Cancer Research Center (CNIO).
3. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl - IRCCS
4. Hospital Universitario La Princesa, Madrid
5. Hospital 12 de Octubre, Madrid
6. Hospital Clínico San Carlos, Madrid
7. Hospital Son Espases, Mallorca
8. Hospital San Pedro de Alcántara
9. Hospital General Universitario de Ciudad Real
10. Hospital Nuestra Señora de Valme
11. Hospital del Mar, Barcelona
12. Centro Oncológico de A Coruña
13. Hospital Universitario Vall Hebron
14. Hospital Universitario La Fe, Valencia

BACKGROUND: Ra223 is a bone-seeking $\alpha$-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately repair DSBs and a significant proportion of mCRPC patients harbor pathogenic germline HR mutations (gHR+). We hypothesize that gHR+ patients, with an impaired ability to repair DSBs, are more likely to respond to Ra223 than gHR- patients.

METHODS: This is an exploratory preplanned analysis of the PRORADIUM study (NCT02925702). PRORADIUM is a prospective observational biomarkers study of mCRPC patients treated with standard-of-care Ra223. Participants were screened for germline mutation in DNA damage and response genes using a multigene panel (Castro et al. J Clin Oncol 2019). Alkaline Phosphatase (ALP) response at 12 weeks was the primary endpoint. PSA response at 12 weeks, overall survival (OS) from Ra223 and clinical and/or radiographic progression free survival (PFS) were also analyzed.

RESULTS: 161 out of 168 patients enrolled in PRORADIUM with available germline testing results were included. A pathogenic gHR mutation was identified in 14 (8.7%) patients (5 BRCA2, 4 ATM, 1 BRCA1, 1 BRCA1+CHEK2, 1 BRIPI, 1 NBN, 1 BLM). Median age was 74 years (range 46-90). Performance status ECOG 1 was recorded in 91% pts. Median number of prior therapy lines for mCRPC was 2 (range 1-4) including at least one taxane in 63% patients. 54% of patients received 5 or 6 cycles of Ra223. After a median follow-up of 20 months, a ≥30% decline in ALP at 12 weeks was observed in 75% of gHR+ compared to 43% of gHR- (p=0.036). No differences in PSA ≥50% decline at 12 weeks (14% vs 8%, p=0.437) and PFS (4.5 vs 5.0 months, p=0.670) were observed by gHR status. A trend towards more prolonged OS from Ra223 was observed in gHR+ (median 14.4 vs 10.6 months, p=0.066).

CONCLUSIONS: In our study, germline HR mutations were associated with improved ALP response, suggesting a benefit from Ra223 in gHR+ patients.

CONFLICT OF INTERESTS: None

FUNDING: Prostate Cancer Foundation; Bayer